LMR Partners LLP Invests $480,000 in Cogent Biosciences, Inc. (NASDAQ:COGT)

LMR Partners LLP purchased a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 44,483 shares of the technology company’s stock, valued at approximately $480,000.

Several other large investors also recently bought and sold shares of COGT. Values First Advisors Inc. acquired a new position in shares of Cogent Biosciences during the 3rd quarter worth approximately $32,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Cogent Biosciences by 38.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock valued at $43,000 after buying an additional 1,104 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Cogent Biosciences in the 3rd quarter worth $76,000. Russell Investments Group Ltd. raised its holdings in shares of Cogent Biosciences by 234.5% during the 1st quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock worth $67,000 after acquiring an additional 7,020 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in shares of Cogent Biosciences during the 3rd quarter valued at about $113,000.

Analyst Ratings Changes

COGT has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Cogent Biosciences in a research report on Monday, November 4th. Citigroup increased their price objective on Cogent Biosciences from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Robert W. Baird lifted their target price on Cogent Biosciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, September 5th. Finally, Wedbush reiterated a “neutral” rating and set a $11.00 price target on shares of Cogent Biosciences in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cogent Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Cogent Biosciences Trading Up 0.8 %

COGT stock opened at $9.06 on Wednesday. The business’s fifty day moving average price is $10.92 and its 200 day moving average price is $9.61. Cogent Biosciences, Inc. has a 12-month low of $3.67 and a 12-month high of $12.61. The company has a market capitalization of $1.00 billion, a PE ratio of -3.65 and a beta of 1.72.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). During the same period in the prior year, the firm posted ($0.64) EPS. Research analysts predict that Cogent Biosciences, Inc. will post -2.4 EPS for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.